The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial‐to‐Mesenchymal Transition
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Ruoyang Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Cell Movement, Epithelial-Mesenchymal Transition, RNA-Binding Proteins, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Province young and middle-aged health science and technology innovation outstanding young talent training program, the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
RBM6, implicated in the progression of multiple tumour types but unexplored in prostate tumours, was found to indicate potential therapeutic implications due to its elevated expression in prostate tumours. To elucidate its molecular function, scratch tests, transwell migration and invasion assays were conducted, with PCR and western blot analyses verifying molecular regulatory relationships. RNA pulldown and RNA immunoprecipitation tests were also employed to investigate underlying mechanisms. Results indicate that RBM6 enhances prostate cell migration by suppressing CDH1, yet ZEB1 overexpression alleviates this suppression. Notably, under these conditions, RBM6's inhibitory effect on MMP16 becomes more pronounced, reducing cell migration ability. Thus, under normal conditions, RBM6 promotes prostate tumour cell migration, but in the context of high ZEB1 expression, it inhibits migration. This shift in RBM6's regulatory capacity towards downstream genes underscores the importance of considering objective conditions in studying RBM6 molecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Key Laboratory of Urinary Tumors, Henan Provincial Health Commission, Zhengzhou, Henan, China.
ORCID-Profile: Ruoyang Liu, Yu Liu, Long Zhang, Xiang Li, Ningyang Li, Fubo Lu, Wansheng Gao, Zhankui Jia, Zhenlin Huang, Jinjian Yang
Förderung
- Henan Province young and middle-aged health science and technology innovation outstanding young talent training program
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, R., Liu, Y., Zhang, L., Li, X., Li, N., Lu, F., Gao, W., Jia, Z., Huang, Z., & Yang, J. (2025). The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial‐to‐Mesenchymal Transition. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70397
Vancouver
Liu R, Liu Y, Zhang L, Li X, Li N, Lu F, et al. The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial‐to‐Mesenchymal Transition. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70397
BibTeX
@article{Liu2025,
author = {Liu, Ruoyang and Liu, Yu and Zhang, Long and Li, Xiang and Li, Ningyang and Lu, Fubo and Gao, Wansheng and Jia, Zhankui and Huang, Zhenlin and Yang, Jinjian},
title = {The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial‐to‐Mesenchymal Transition},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70397}
}
EUVIMED